» Articles » PMID: 33917405

Cancer Cells' Metabolism Dynamics in Renal Cell Carcinoma Patients' Outcome: Influence of GLUT-1-Related Hsa-miR-144 and Hsa-miR-186

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Apr 30
PMID 33917405
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The cancer cells' metabolism is altered due to deregulation of key proteins, including glucose transporter 1 (GLUT-1), whose mRNA levels are influenced by microRNAs (miRNAs). Renal cell carcinoma (RCC) is the most common and lethal neoplasia in the adult kidney, mostly due to the lack of accurate diagnosis and follow-up biomarkers. Being a metabolic associated cancer, this study aimed to understand the hsa-miR-144-5p and hsa-miR-186-3p's potential as biomarkers of clear cell RCC (ccRCC), establishing their role in its glycolysis status. Using three ccRCC lines, the intra- and extracellular levels of both miRNAs, GLUT-1's mRNA expression and protein levels were assessed. Glucose consumption and lactate production were evaluated as glycolysis markers. A decrease of intracellular levels of these miRNAs and increase of their excretion was observed, associated with an increase of GLUT-1's levels and glycolysis' markers. Through a liquid biopsy approach, we found that RCC patients present higher plasmatic levels of hsa-miR-186-3p than healthy individuals. The Hsa-miR144-5p's higher levels were associated with early clinical stages. When patients were stratified according to miRNAs plasmatic levels, low plasmatic levels of hsa-miR-144-5p and high plasmatic levels of hsa-miR-186-3p (high-risk group) showed the worst overall survival. Thus, circulating levels of these miRNAs may be potential biomarkers of ccRCC prognosis.

Citing Articles

Pan-cancer analysis of SLC2A family genes as prognostic biomarkers and therapeutic targets.

Liu Y, Li X, Yang J, Chen S, Zhu C, Shi Y Heliyon. 2024; 10(8):e29655.

PMID: 38655365 PMC: 11036058. DOI: 10.1016/j.heliyon.2024.e29655.


Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer.

Liao M, Yao D, Wu L, Luo C, Wang Z, Zhang J Acta Pharm Sin B. 2024; 14(3):953-1008.

PMID: 38487001 PMC: 10935242. DOI: 10.1016/j.apsb.2023.12.003.


A group of three miRNAs can act as candidate circulating biomarkers in liquid biopsies from melanoma patients.

De Martino E, Gandin I, Azzalini E, Massone C, Pizzichetta M, Giulioni E Front Med (Lausanne). 2023; 10:1180799.

PMID: 37387784 PMC: 10301821. DOI: 10.3389/fmed.2023.1180799.


PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.

Badoiu S, Greabu M, Miricescu D, Stanescu-Spinu I, Ilinca R, Balan D Int J Mol Sci. 2023; 24(9).

PMID: 37176098 PMC: 10179314. DOI: 10.3390/ijms24098391.


KIF2C accelerates the development of non-small cell lung cancer and is suppressed by miR-186-3p via the AKT-GSK3β-β-catenin pathway.

Guo J, Zhang W, Sun L, Yu H, Wang Y, Feng L Sci Rep. 2023; 13(1):7288.

PMID: 37142638 PMC: 10160078. DOI: 10.1038/s41598-023-30073-5.


References
1.
Schodel J, Grampp S, Maher E, Moch H, Ratcliffe P, Russo P . Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. Eur Urol. 2015; 69(4):646-657. PMC: 5012644. DOI: 10.1016/j.eururo.2015.08.007. View

2.
Filipow S, Laczmanski L . Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response. Front Genet. 2019; 10:169. PMC: 6421259. DOI: 10.3389/fgene.2019.00169. View

3.
Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

4.
Nogueira I, Dias F, Morais M, Teixeira A, Medeiros R . Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2α as molecular triggers?. Future Oncol. 2019; 15(20):2361-2370. DOI: 10.2217/fon-2019-0067. View

5.
Cai J, Wu J, Zhang H, Fang L, Huang Y, Yang Y . miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res. 2012; 73(2):756-66. DOI: 10.1158/0008-5472.CAN-12-2651. View